Investor Relations

Investor Relations

Company Overview

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products are based on our recombinant human collagen, that is produced with CollPlant’s proprietary plant based genetic engineering technology.

Our products address indications for the diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, we entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant’s BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

Corporate Presentation

Corporate Presentation

Download Corporate Presentation

Stock Information

Upcoming Events

Annual and Extraordinary General Meeting of Shareholders

Dec 31, 2019 • 10:00am IST

View All Events

Latest Financial Results

Q3 2019

Quarter Ended Sep 30, 2019

Latest Annual Filing

Fiscal Year Ended Dec 31, 2018

View Filing

Investor Contact Information

Company

CollPlant Biotechnologies Ltd.
4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Corporate Profile®
Laurel Moody
1185 Avenue of the Americas 3rd Floor
New York, NY 10036
T: +1 212 931 8787 Ext 101

Transfer Agent

The Bank of New York Mellon
Depositary Receipts Division - Global Client Solutions
Arlene C. Villareal
Vice President
101 Barclay Street, 22W
New York, NY 10286
T: 212-815-8162
Arlene.villareal@bnymellon.com

® 2019 CollPlant Ltd. All rights reserved. Version: CPW 02-16

Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.